Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5908 - A Phase 2 Clinical Investigation of BPM31510-IV (Ubidecarenone) in patients with advanced Pancreatic Cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Clinical Research

Tumour Site

Pancreatic Cancer

Presenters

Anna Niewiarowska

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

A.A. Niewiarowska1, D.M. Lucius2, R. Sarangarajan3, N.R. Narain4, R. Ramanathan5, P. Ritch6, J. Strauss7, M. Kundranda8, D. Propper9

Author affiliations

  • 1 Hematology, Vita Medical Associates, 18015 - Bethlehem/US
  • 2 Clinical Operations, BERG, LLC, 01701 - Framingham/US
  • 3 Biosystems, BERG, LLC, 01701 - Framingham/US
  • 4 Biosystems, Analytics, & Precision Medicine, BERG, LLC, 01701 - Framingham/US
  • 5 Oncology, Mayo Clinic Cancer Center, 85259 - Scottsdale/US
  • 6 Hematology And Oncology, Medical College of Wisconsin, 53226 - Milwaukee/US
  • 7 Oncology, Mary Crowley Medical Research Center, 75230 - Dallas/US
  • 8 Gastrointestinal Medical Oncology, Medical Oncology, Banner MD Anderson Cancer Center, 85234 - Gilbert/US
  • 9 Oncology, St. Bartholomew's Hospital, EC1A 7BE - London/GB
More

Resources

Abstract 5908

Background

BPM31510-IV is an ubidecarenone containing intravenous nanodispersion targeting the metabolic machinery in cancer, shifting bioenergetics from lactate dependency towards mitochondrial OxPhos and reversing the Warburg effect. BPM31510-IV enables delivery of ubidecarenone preferentially into cancer cell mitochondria, generating reactive oxygen species and activation of apoptosis. In a phase I study, BPM31510-IV was well-tolerated as a monotherapy, and in combination with gemcitabine, with an established maximum tolerated dose (MTD) of 110mg/kg and thus, formed the basis for the Phase 2 investigation.

Trial design

In this study eligible patients (aged ≥ 18 y) relapsed/refractory to standard treatment for advanced metastatic pancreatic cancer and meeting inclusion/exclusion criteria receives either two 72 hr infusions of 110mg/kg BPM31510-IV or in combination with gemcitabine (1000 mg/m3 over 30 min, weekly x 3 weeks every 28 days). Tumor response is evaluated at wk 10, and then every 8 wks. This study occurs in two parts: Part 1 is designed to enroll 10 patients in the BPM31510-IV (monotherapy arm) and 10 patients in the BPM31510-IV plus gemcitabine (combination therapy arm) with intent to enroll an additional 15 patients (Part 2) into the applicable treatment arm(s). Endpoints will include overall response rate in both groups along with overall survival, progression-free survival, and time to progression. Additionally, patient reported Quality of Life using the validated FACT-HEP as well as tumor response measured by CA 19-9 levels will be combined with multi-omic molecular profiling to assess adaptive molecular responses. An exploratory objective of this study is to comprehensively perform multi-omic profiling for identification of biomarker panels for patient stratification for later stages of clinical development.

Clinical trial identification

NCT02650804.

Legal entity responsible for the study

BERG, LLC.

Funding

BERG, LLC.

Editorial Acknowledgement

Khampaseuth Thapa. BERG, LLC.

Disclosure

A.A. Niewiarowska, R. Ramanathan, P. Ritch: Research sponsorship: BERG, LLC. D.M. Lucius: Employee, stock owner: BERG, LLC. R. Sarangarajan: Co-founder, employee, stock options owner: BERG, LLC. N.R. Narain: Co-founder, president & CEO, stock options owner: BERG, LLC. J. Strauss: Research sponsorship: BERG, LLC; stock & other ownership: Abbott, Abbvie, Bristol-Myers Squibb, Intuitive surgical, Merck. M. Kundranda: Research sponsorship: BERG, LLC; Honoraria: Bayer. D. Propper: Research sponsorship: BERG, LLC; Consulting, advisory role: BMS; Speaker\'s bureau: Merck; Travel, accommodations, expenses: Celgene.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.